Exact Sciences (EXAS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release — Positive
EXAS Zacks Investment Research — October 27, 2025Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Freshpet (FRPT) Reports Next Week: Wall Street Expects Earnings Growth — Positive
FRPT Zacks Investment Research — October 27, 2025Freshpet (FRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release — Neutral
HIMS Zacks Investment Research — October 27, 2025Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release — Positive
HALO Zacks Investment Research — October 27, 2025Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic (HOLX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release — Neutral
HOLX Zacks Investment Research — October 27, 2025Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Idexx Laboratories (IDXX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release — Positive
IDXX Zacks Investment Research — October 27, 2025Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Helios Technologies (HLIO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release — Neutral
HLIO Zacks Investment Research — October 27, 2025Helios Technologies (HLIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Palomar (PLMR) to Report Q3 Results: Wall Street Expects Earnings Growth — Positive
PLMR Zacks Investment Research — October 27, 2025Palomar (PLMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Palantir Technologies Inc. (PLTR) Earnings Expected to Grow: Should You Buy? — Neutral
PLTR Zacks Investment Research — October 27, 2025Palantir Technologies (PLTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Krystal Biotech, Inc. (KRYS) Reports Next Week: Wall Street Expects Earnings Growth — Positive
KRYS Zacks Investment Research — October 27, 2025Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q3 Release — Neutral
TGTX Zacks Investment Research — October 27, 2025TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Transcat, Inc. (TRNS) Reports Next Week: Wall Street Expects Earnings Growth — Positive
TRNS Zacks Investment Research — October 27, 2025Transcat (TRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QuinStreet (QNST) Expected to Beat Earnings Estimates: Can the Stock Move Higher? — Positive
QNST Zacks Investment Research — October 27, 2025QuinStreet (QNST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? — Positive
VRTX Zacks Investment Research — October 27, 2025Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex (VERX) Earnings Expected to Grow: Should You Buy? — Neutral
VERX Zacks Investment Research — October 27, 2025Vertex (VERX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eni Q3 Earnings & Revenues Beat on Higher Hydrocarbon Production — Positive
E Zacks Investment Research — October 27, 2025E Q3 earnings and revenues beat estimates on the back of higher hydrocarbon output and refining gains.
RVTY Q3 Earnings Beat, Sales In Line, '25 EPS View Raised — Positive
RVTY Zacks Investment Research — October 27, 2025Revvity beats on Q3 earnings and raises 2025 EPS view, as balanced segment performance offsets margin pressure.
Exclusive: US Department of Energy forms $1 billion supercomputer and AI partnership with AMD — Positive
AMD Reuters — October 27, 2025The U.S. has formed a $1 billion partnership with Advanced Micro Devices to construct two supercomputers that will tackle large scientific problems ranging from nuclear power to cancer treatments to national security, Energy Secretary Chris Wright and AMD CEO Lisa Su told Reuters.
Best Momentum Stock to Buy for Oct. 27th — Positive
GM ISRG PRM Zacks Investment Research — October 27, 2025PRM, GM and ISRG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 27, 2025.
Bank of Marin (BMRC) Reports Q3 Earnings: What Key Metrics Have to Say — Neutral
BMRC Zacks Investment Research — October 27, 2025While the top- and bottom-line numbers for Bank of Marin (BMRC) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
